CN109641887B - 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 - Google Patents
可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 Download PDFInfo
- Publication number
- CN109641887B CN109641887B CN201780051410.0A CN201780051410A CN109641887B CN 109641887 B CN109641887 B CN 109641887B CN 201780051410 A CN201780051410 A CN 201780051410A CN 109641887 B CN109641887 B CN 109641887B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- formula
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353298P | 2016-06-22 | 2016-06-22 | |
| US62/353,298 | 2016-06-22 | ||
| PCT/US2017/038549 WO2017223202A1 (en) | 2016-06-22 | 2017-06-21 | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109641887A CN109641887A (zh) | 2019-04-16 |
| CN109641887B true CN109641887B (zh) | 2022-09-20 |
Family
ID=59276859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780051410.0A Active CN109641887B (zh) | 2016-06-22 | 2017-06-21 | 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10836759B2 (enExample) |
| EP (1) | EP3475276B1 (enExample) |
| JP (1) | JP6987798B2 (enExample) |
| CN (1) | CN109641887B (enExample) |
| AU (1) | AU2017281088B2 (enExample) |
| ES (1) | ES2880347T3 (enExample) |
| WO (1) | WO2017223202A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| WO2016044787A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US9624175B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| SMT202300073T1 (it) | 2018-05-16 | 2023-05-12 | Forma Therapeutics Inc | Inibizione di idh-1 mutante |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102985557A (zh) * | 2009-03-13 | 2013-03-20 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| CN105209460A (zh) * | 2013-03-14 | 2015-12-30 | 诺华股份有限公司 | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 |
| WO2016106331A1 (en) * | 2014-12-22 | 2016-06-30 | The United States Of America | Mutant idh1 inhibitors useful for treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010229968A1 (en) | 2009-03-24 | 2011-10-13 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
-
2017
- 2017-06-21 JP JP2018567108A patent/JP6987798B2/ja active Active
- 2017-06-21 AU AU2017281088A patent/AU2017281088B2/en active Active
- 2017-06-21 CN CN201780051410.0A patent/CN109641887B/zh active Active
- 2017-06-21 ES ES17735296T patent/ES2880347T3/es active Active
- 2017-06-21 WO PCT/US2017/038549 patent/WO2017223202A1/en not_active Ceased
- 2017-06-21 US US16/312,206 patent/US10836759B2/en active Active
- 2017-06-21 EP EP17735296.0A patent/EP3475276B1/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102985557A (zh) * | 2009-03-13 | 2013-03-20 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| CN105209460A (zh) * | 2013-03-14 | 2015-12-30 | 诺华股份有限公司 | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 |
| WO2016106331A1 (en) * | 2014-12-22 | 2016-06-30 | The United States Of America | Mutant idh1 inhibitors useful for treating cancer |
| CN107428690A (zh) * | 2014-12-22 | 2017-12-01 | 美国政府健康及人类服务部 | 可用于治疗癌症的突变idh1抑制剂 |
Non-Patent Citations (1)
| Title |
|---|
| Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase;Zheng, BS et al.;《ACS MEDICINAL CHEMISTRY LETTERS》;20130503;第4卷(第6期);第542-546页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3028999A1 (en) | 2017-12-28 |
| WO2017223202A1 (en) | 2017-12-28 |
| EP3475276B1 (en) | 2021-03-31 |
| JP2019518770A (ja) | 2019-07-04 |
| AU2017281088B2 (en) | 2021-05-27 |
| US20190241551A1 (en) | 2019-08-08 |
| CN109641887A (zh) | 2019-04-16 |
| EP3475276A1 (en) | 2019-05-01 |
| ES2880347T3 (es) | 2021-11-24 |
| US10836759B2 (en) | 2020-11-17 |
| JP6987798B2 (ja) | 2022-01-05 |
| AU2017281088A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6901394B2 (ja) | 癌の処置に有用な変異型ｉｄｈ１阻害剤 | |
| JP6987798B2 (ja) | 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 | |
| EP2396325B1 (en) | Derivatives of azaindoles as inhibitors of protein kinases abl and src | |
| JP2007501272A (ja) | 置換イミダゾロピラジンおよびトリアゾロピラジン誘導体類：ｇａｂａａレセプタリガンド類 | |
| WO2018214866A1 (zh) | 一种氮杂芳基衍生物、其制备方法和在药学上的应用 | |
| TW202200575A (zh) | 一種免疫抑制劑、其製備方法和應用 | |
| WO2021126923A1 (en) | Cd206 modulators their use and methods for preparation | |
| Xue et al. | Discovery of 4, 7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido [5, 4-b] pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors | |
| US20210139492A1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
| JP2007500130A (ja) | ベンゾジアゼピン受容体リガンドである、イミダゾ−ピリミジン及びトリアゾロ−ピリミジン | |
| JPWO2013081094A1 (ja) | イミダゾ［１，２−ａ］ピリジン誘導体及びその医薬用途 | |
| US20240190864A1 (en) | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | |
| JP2023512482A (ja) | Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体 | |
| CN103664903A (zh) | 苯氮卓类化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |